Gradient Investments LLC Humanigen, Inc Transaction History

Gradient Investments LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 12, 2022	BUY	$3.66 - $8.22 $1,098 - $2,466	300 Added 42.86%	1,000 $4,000
Q3 2021 Oct 18, 2021	BUY	$5.93 - $17.83 $3,558 - $10,697	600 Added 600.0%	700 $4,000
Q2 2021 Jul 12, 2021	SELL	$13.54 - $22.74 $1,354 - $2,274	-100 Reduced 50.0%	100 $2,000
Q1 2021 Apr 21, 2021	BUY	$12.91 - $23.83 $2,582 - $4,766	200 New	200 $4,000

558K

Ticker HGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,661,000
Description
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...

Get notified when there are updates to the investment portfolio of Gradient Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Gradient Investments LLC with notifications on news.